Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis

Fernando Cavalcanti, GONZALEZ-REY ELENA, Mario Delgado, Clara P. Falo, Leyre Mestre, Carmen Guaza, Francisco O’Valle, Michele M. P. Lufino, Jordi Xaus, Cristina Mascaró, Serena Lunardi, Natalia Sacilotto, Paola Dessanti, David Rotllant, Xavier Navarro, Mireia Herrando-Grabulosa, carlos buesa, Tamara Maes

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

3 Cites (Scopus)
1 Descàrregues (Pure)

Resum

Lysine specific demethylase 1 (LSD1; also known as KDM1A), is an epigenetic modulator that modifies the histone methylation status. KDM1A forms a part of protein complexes that regulate the expression of genes involved in the onset and progression of diseases such as cancer, central nervous system (CNS) disorders, viral infections, and others. Vafidemstat (ORY-2001) is a clinical stage inhibitor of KDM1A in development for the treatment of neurodegenerative and psychiatric diseases. However, the role of ORY-2001 targeting KDM1A in neuroinflammation remains to be explored. Here, we investigated the effect of ORY-2001 on immune-mediated and virus-induced encephalomyelitis, two experimental models of multiple sclerosis and neuronal damage. Oral administration of ORY-2001 ameliorated clinical signs, reduced lymphocyte egress and infiltration of immune cells into the spinal cord, and prevented demyelination. Interestingly, ORY-2001 was more effective and/or faster acting than a sphingosine 1-phosphate receptor antagonist in the effector phase of the disease and reduced the inflammatory gene expression signature characteristic ofEAE in the CNS of mice more potently. In addition, ORY-2001 induced gene expression changes concordant with a potential neuroprotective function in the brain and spinal cord and reduced neuronal glutamate excitotoxicity-derived damage in explants. These results pointed to ORY-2001 as a promising CNS epigenetic drug able to target neuroinflammatory and neurodegenerative diseases and provided preclinical support for the subsequent design of early-stage clinical trials.
Idioma originalEnglish
Número d’article1420
Nombre de pàgines33
RevistaPharmaceutics
Volum14
Número7
DOIs
Estat de la publicacióPublicada - de jul. 2022

Fingerprint

Navegar pels temes de recerca de 'Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis'. Junts formen un fingerprint únic.

Com citar-ho